On March 8, 2022 Cothera Bioscience, the parent company of Percans Oncology, reported that it received approval from the National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to test its targeted MYC mutation inhibitor PC-002 as a first-line or second-line treatment for drug-resistant or relapsed high-grade B-cell lymphoma (HGBCL) (Press release, Cothera Bioscience, MAR 8, 2022, View Source [SID1234618849]). The NMPA completed its review of the project in just 45 working days, demonstrating the strong support of regulatory authorities for innovative drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PC-002, the core product of Cothera Bioscience, is a first-in-class small molecule drug targeting MYC-mutated tumors. With a unique mechanism of action (MOA), PC-002 selectively induces MYC protein degradation and cell apoptosis in MYC-dependent tumors. With more than 50% of human cancers showing increased expression, MYC is regarded as one of the most important yet "undruggable" cancer targets. Via its unique mechanism, PC-002 selectively kills tumor cells with MYC mutation and may potentially target multiple indications in cancers.